Breaking New Ground in Cervical Metastatic Carcinoma of Unknown Primary: Neoadjuvant Immunochemotherapy's Pathologic Regression and Survival Advantage
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
Q Jin, X Zhang, J Yuan, Q Fang, W Du
Annals of Surgical Oncology, 2026
Springer
Background Cervical metastatic carcinoma of unknown primary (CMCUP) poses significant therapeutic challenges because of its aggressive biology and the absence of standardized treatment protocols. While neoadjuvant immunochemotherapy (NICT) has demonstrated efficacy across various malignancies, its application in CMCUP remains poorly characterized. Methods This retrospective cohort study evaluated 98 consecutive patients with CMCUP treated at a tertiary cancer center between 2015 and 2024. Patients were …
